result lose step larg due ou
biolog extrem cartiva roughli
extrem cartiva roughli in-lin cse total sale mil
mil estim driven part time biolog sale certain ou
stock distributor upper lower extrem roughli line
modest upsid us off-set slower-than-expect growth ou cartiva sale
in-lin estim mil vs cse mil although pro forma
perform inform provid estim organ growth came
estim term earn perform estim mil
miss total sale equat shortfal ep
chang model beyond decreas sale estim
averag ep estim come penni unchang
price expect track in-lin deal price remain bullish
deal expect wmgi stock perform driven deal price rather
fundament overal view deal syk perspect make
strateg sens significantli enhanc syk extrem portfolio improv syk
market share shoulder foot ankl market posit compani
launch success mako robot surgeri applic shoulder elbow
basi wmgi formerli tornier market-lead shoulder portfolio continu
view prospect compet bid rel unlik given small
number potenti acquir premium paid novemb
valuat target price neutral rate in-lin deal
price risk sale forc product issu key product delay failur progress ltp
goal potenti new litig regulatori qualiti issu
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
wright medic global manufactur provid medic devic
equip treatment musculoskelet disord
emphasi upper lower extrem
target price base compet bid
repres premium offer
grey target price base deal fall
stock revert back close price deal rumor
publish press
 close
summari result wmgi
 upper extrem primarili driven on-going launch flex reviv
revis shoulder system on-going adopt blueprint perform revers glenoid system
simplic shoulder system
 lower extrem primarili driven cartiva net sale mil
vs cse mil biolog mil mil sale driven core
biolog product augment inject ou sale decreas due time
sale stock distributor
chang model
make minor modif beyond top-lin estim base
number beyond decreas sale estim averag
ep estim come penni
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
